Site Supporters

Celgene Corporation and its employees are working relentlessly to provide solutions for unmet medical needs in cancer and debilitating inflammatory diseases. Our goal is to provide next-generation therapies that deliver quality outcomes for better healthcare. Celgene is dedicated to improving healthcare by delivering more disease-altering therapies to patients in need. In fact, there are more than 200 ongoing clinical trials at major medical centers worldwide using innovative compounds from Celgene. These promising drugs include many high-potential compounds in our rich regulatory pipeline. These investigational compounds are being actively studied in clinical trials for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocytic leukemia (CLL), non-Hodgkins lymphoma, glioblastoma, ovarian, pancreatic and prostate cancer.

Celgene is committed to improving the lives of patients worldwide. By utilizing the latest advances in molecular and cellular research to develop novel therapies that target the mechanisms of disease at their source, Celgene is making potentially life-saving treatments a reality for the millions of patients around the world fighting cancer and other debilitating diseases.